Medical abortion at 10-20 weeks

Termination Of Pregnancy at 64-140 days

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN49711898

Enrollment

670

Registered

2013-10-02

Start date

2014-01-01

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy of 64-140 days duration Pregnancy and Childbirth

Interventions

Women are randomized to receive misoprostol treatment (orally) (as in WHO Safe abortion guidelines, 2012) either 24 hours or 48 hours after mifepristone.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Good general health 2. Older than the age for legal consent 3. Requesting and eligible for legal termination of pregnancy 4. Duration of pregnancy 64-140 days on Day 1 (mifepristone administration), verified by ultrasound

Exclusion criteria

Exclusion criteria: 1. No contra-indications towards mifepristone and misoprostol 2. No serious present or past ill health 3. Molar or extrauterine pregnancy or threathend abortion, >1 low segment C-section

Design outcomes

Primary

Measure	Time frame
Efficacy (expulsion of pregnancy) at 24 h	—

Secondary

Measure	Time frame
1. Induction-to-abortion interval: This is the time interval from the administration of the first dose of misoprostol until expulsion of the products of conception 2. Possible side-effects: Side effects are recorded during the whole study, from the administration of mifepristone until the follow-up visit, or beyond, if needed 3. Women's perceptions: Women's perception of the method are recorded at an interview during the follow-up visit about two weeks after treatment	—

Measure

Time frame

1. Induction-to-abortion interval: This is the time interval from the administration of the first dose of misoprostol until expulsion of the products of conception 2. Possible side-effects: Side effects are recorded during the whole study, from the administration of mifepristone until the follow-up visit, or beyond, if needed 3. Women's perceptions: Women's perception of the method are recorded at an interview during the follow-up visit about two weeks after treatment

—

Countries

India, Sweden, Switzerland, Thailand, Viet Nam

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026